Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub
505(b)(2) Hybrid Risperidone Long-Acting Injectable Given Name Uzedy
Teva maintains that the clinical data package looks sounds for it and partner MedinCell’s proposed 505(b)(2) hybrid risperidone long-acting injectable product, as the firms look to muscle in on the multi-billion-dollar LAI schizophrenia market next year.
You may also be interested in...
Teva Hopes For Revenue Growth For First Time Since 2017
The company’s new CEO Richard Francis is aiming for revenue growth this year; it would be the first time since 2017.
Teva: We Believe In Biosimilars, But Pipeline And Timing Come First
Teva’s newly appointed CEO Richard Francis has underlined the company’s commitment to biosimilars, buoyed by his experience overseeing their progress at his former employer Sandoz.
Second Long-Acting Antipsychotic Sampling Program Cleared By OIG Advisory Opinion
The second nearly identical advisory opinion that allows free samples of long-acting antipsychotics to certain hospitals without fear of kickback violations shows inefficiencies of the HHS OIG system for clarifying its fraud and abuse authorities.